Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced results from an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting on longer follow-up data from the IMerge Phase 2 clinical trial of imetelstat, the Company's first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). The data in the presentation focused on the patients who achieved greater than one-year sustained continuous transfusion independence and included their baseline characteristics, clinical benefits and observed safety profile.

Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients

Bionano Genomics

Muscle Maker

The Very Good Food Co

Penny stocks to watch this week. The post 4 Penny Stocks To Watch With Big News In December 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch With Big News In December 2022

Geron to Participate in Stifel 2022 Healthcare Conference

Geron Corporation (NASDAQ:GERN ) Q3 2022 Results Conference Call November 3, 2022 9:00 AM ET Company Participants Aron Feingold - Vice President of Investor Relations and Corporate Communications John Scarlett - Chairman and Chief Executive Officer Olivia Bloom - Executive Vice President and Chief Financial Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President of Corporate Strategy and Chief Commercial Officer Conference Call Participants Kalpit Patel - B. Riley FBR Stephen Willey - Stifel Gil Blum - Needham & Company Joel Beatty - Baird Vernon Bernardino - H.C.

Geron Corporation (GERN) Q3 2022 Earnings Call Transcript

Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS

Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones

Aeglea BioTherapeutics

Data I/O

Perpetua Resources Corp

Penny stocks to watch this week with news. The post 5 Top Penny Stocks To Watch With News Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Watch With News Before Next Week

Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022

Here is how Geron (GERN) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have performed compared to their sector so far this year.

Is Geron (GERN) Outperforming Other Medical Stocks This Year?

AbbVie

ADMA Biologics

Prometheus Biosciences

SIGA Technologies

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

100% technical buy signals. 7 new highs and up 23.83% in the last month.

Geron - Low-Priced Giant

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of John F. McDonald as an independent member of its Board of Directors, effective September 7, 2022. “With his three decades in the biopharmaceutical industry across business development and investment and corporate strategy, John is a highly respected and seasoned R&D executive with valuable pharmaceutical and biotechnology experience. We

Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to present in-person at the following investor conferences in New York City: Morgan Stanley 20th Annual Global Healthcare Conference Fireside chat on Monday, September 12, 2022, at 5:25 p.m.

Geron to Present at Upcoming Investor Conferences

Party City Holdco

Summit Therapeutics

The Metals Co

Penny stocks for your September watch list. The post 4 Penny Stocks To Watch For September 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch For September 2022

The company said it expects to submit a new drug application for its lead candidate early next year.

Why Geron's Shares Rose 14.78% on Wednesday

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 study evaluating imetelstat, a first-in-class telomerase inhibitor, in combination with ruxolitinib in patients with frontline myelofibrosis (MF). “We designed the Phase 1 IMproveMF study based on preclinical data that showed the sequential treatment of ruxolitinib followed by imetelstat had a selec

Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

Geron Corporation (NASDAQ:GERN ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications Dr. John Scarlett - Chairman and CEO Olivia Bloom - Executive Vice President, Finance and CFO and Treasurer Dr. Faye Feller - Executive Vice President and CMO Anil Kapur - Executive Vice President, Corporate Strategy and CCO Conference Call Participants Kalpit Patel - B. Riley Securities Joel Beatty - Baird Stephen Willey - Stifel Gil Blum - Needham & Company Operator Good afternoon.

Geron Corporation's (GERN) CEO Dr. John Scarlett on Q2 2022 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones. “We continue to focus intently on our plans for a catalyst-rich next two years, during which we expect to transform Geron from a development stage to commercial company,” said John

Geron Corporation Reports Second Quarter 2022 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as key upcoming expected milestones at 4:30 p.m. ET the same day. A live webcast of the conference call and related presentat

Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022

Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 at 12:35 p.m. ET. A webcast of the presentation will be available through th

Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

Canopy Growth

IAMGOLD

Mullen Automotive

Platinum Group Metals

ECA Marcellus Trust

If you think the volatility in the broader indices isn't enough excitement, here are the best penny stocks to consider under $3. The post 7 Best Penny Stocks Under $3 to Buy in July appeared first on InvestorPlace.

7 Best Penny Stocks Under $3 to Buy in July

Blue Apron

Mega Matrix Corp

Sorrento Therapeutics Inc

Penny stocks to watch right now The post Best Penny Stocks To Watch? 4 For Your Independence Day List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Watch? 4 For Your Independence Day List

Hercules Capital

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million. “This expansion of our debt facility provides potential access of up to $50 million in additional non-dilutive capital in 2023, the year in which we expect top-line results from the Phase 3 IMerge tri

Geron Corporation Announces Expansion of Existing Loan Facility

AcelRx Pharmaceuticals

Connect Biopharma Holdings

Can these penny stocks climb this week? The post Hot Penny Stocks That Are Climbing Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks That Are Climbing Right Now

News for Geron Stock (GERN)